TRCT
NRIX icon

Tower Research Capital (TRC)’s Nurix Therapeutics NRIX Stock Holding History

Tower Research Capital (TRC)’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47K Sell
1,936
-13,464
-87% -$229K ﹤0.01% 2785
2026
Q1 		$239K Buy
15,400
+10,889
+241% +$181K 0.01% 1485
2025
Q4 		$85.6K Buy
4,511
+378
+9% +$5.43K ﹤0.01% 2041
2025
Q3 		$38.2K Sell
4,133
-2,280
-36% -$23.7K ﹤0.01% 2736
2025
Q2 		$73K Buy
6,413
+3,475
+118% +$37.6K ﹤0.01% 2641
2025
Q1 		$34.9K Sell
2,938
-11,947
-80% -$200K ﹤0.01% 2499
2024
Q4 		$280K Buy
14,885
+12,036
+422% +$276K 0.01% 1461
2024
Q3 		$64K Sell
2,849
-3,755
-57% -$85.1K ﹤0.01% 2580
2024
Q2 		$138K Buy
6,604
+5,306
+409% +$82.6K ﹤0.01% 2355
2024
Q1 		$19.1K Sell
1,298
-22,307
-95% -$240K ﹤0.01% 3043
2023
Q4 		$244K Buy
23,605
+22,717
+2,558% +$156K ﹤0.01% 1942
2023
Q3 		$6.98K Sell
888
-1,736
-66% -$15.9K ﹤0.01% 4527
2023
Q2 		$26.2K Sell
2,624
-8,480
-76% -$86.5K ﹤0.01% 3144
2023
Q1 		$99K Buy
11,104
+10,405
+1,489% +$108K ﹤0.01% 1879
2022
Q4 		$8K Sell
699
-9,336
-93% -$113K ﹤0.01% 4432
2022
Q3 		$131K Buy
10,035
+5,506
+122% +$87.1K ﹤0.01% 2312
2022
Q2 		$57K Buy
4,529
+2,403
+113% +$27.2K ﹤0.01% 2758
2022
Q1 		$30K Sell
2,126
-2,559
-55% -$45.4K ﹤0.01% 3154
2021
Q4 		$136K Buy
4,685
+1,950
+71% +$59.1K ﹤0.01% 2035
2021
Q3 		$82K Sell
2,735
-175
-6% -$5.4K ﹤0.01% 2570
2021
Q2 		$77K Sell
2,910
-686
-19% -$20.1K ﹤0.01% 2643
2021
Q1 		$112K Buy
3,596
+994
+38% +$37.6K ﹤0.01% 2507
2020
Q4 		$86K Buy
2,602
+814
+46% +$27K ﹤0.01% 2502
2020
Q3 		$62K Buy
+1,788
New +$45.1K ﹤0.01% 3444

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tower Research Capital (TRC)'s NRIX Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Nurix Therapeutics (NRIX) stake by 87% in Q2 2026, selling an estimated $229K and leaving 1,936 shares worth $47K. The position accounts for ﹤0.01% of the portfolio, ranked #2785.

Tower Research Capital (TRC) first reported a position in NRIX in Q3 2020 and has held it in 24 quarters since. The position peaked at $280K in Q4 2024. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Tower Research Capital (TRC) held 1,936 shares of Nurix Therapeutics worth $47K as of Q2 2026.
  • Tower Research Capital (TRC) sold 13,464 Nurix Therapeutics shares in Q2 2026, an estimated $229K.
  • Nurix Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2785 holding.
  • Tower Research Capital (TRC) first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • Tower Research Capital (TRC)'s Nurix Therapeutics position peaked at $280K in Q4 2024.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.